Overview
| 别名 | Histone-lysine N-methyltransferase MECOM; Ecotropic virus integration site 1 protein homolog; EVI-1; MDS1 and EVI1 complex locus protein; Myelodysplasia syndrome 1 protein; Myelodysplasia syndrome-associated protein 1 |
| 基因名 | MECOM |
| UniProt ID | Q03112 |
| 反应种属 | Human |
| 应用 | WB |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 7F4-F6-T1 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 138 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:1000 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | MDS1 and EVI1 complex locus (MECOM) encodes transcriptional regulators that function as both repressors and coactivators to modulate genes involved in hematopoiesis, development, and stem cell differentiation. MECOM proteins localize to the nucleus, where they bind specific DNA motifs via C2H2 zinc fingers and recruit histone-modifying cofactors such as CBP/p300 and histone methyltransferases. These interactions shape chromatin architecture and regulate signaling pathways, including TGF-β/SMAD, Notch, and VEGF. MECOM is essential for the maintenance of hematopoietic stem cells and endothelial lineage specification. Pathologically, MECOM acts as a proto-oncogene; its overexpression or genomic rearrangement is a hallmark of aggressive myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), where it is associated with poor clinical prognosis. |
检测原理